Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA vasculitis associated nephritis (IgAVN) is common in adults and can lead to significant morbidity. However, the long-term prognosis remains controversial. The aim of this study is to develop a nomogram in conjunction with clinic risk factors and pathologic indicators to predict the renal progression in adults IgAVN patients.
In this two-center retrospective study, we screened patients with IgAVN confirmed by renal biopsy between January 1, 2008 and December 31, 2023. Data on patient‘s demographics, clinical information and follow-up results were collected. The renal pathological findings of patients were re-evaluated by Oxford classification. The COX regression and Least absolute shrinkage and selection operator (LASSO) regression were used to screen risk factors, which were ultimately determined based on the clinical background and previous literature reporting risk factors associated with renal progression. The primary outcome of the nomogram was estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2 with ≥30% decrease from baseline or end-stage renal disease. The discrimination and accuracy of the nomogram were verified internally by C-index and calibration curve, and externally verified by calculating their performance in the validation cohort.
A total of 542 patients were screened, among whom 323 (60%) met the criteria and were divided into a development cohort (n=225) from the Sichuan Provincial People's Hospital and a validation cohort (n=98) from the First People's Hospital of Liangshan. The median follow-up time were 48.0 months (IQR 21.0-96.0) and 49.0 months (IQR 30.25-73.25) in these two cohorts respectively. Characteristics of patients were well balanced across the two cohorts except age, hypertension, uric acid, serum albumin, serum IgG, serum IgA, and Oxford classification of S lesions. By the last follow-up, 7 (2.17%) of 323 patients had undergone renal replacement therapy. Additionally, 31(9.60%) experienced eGFR progression. Age, gender, baseline eGFR, serum IgA, Oxford classification of E and S lesions were included in the final nomogram. The C-index of the overall survival model was 0·86 (95% CI: 0·77–0·94). The C-index was > 70% in both internal [0.82 (95%CI: 0.78-0.85)] and external [0.79 (95%CI :0.65-0.93)] validations. The area under the receiver operating characteristic (ROC) curve for predicting clinical outcomes was 0·965 (95% CI: 0·899–0·986) in the development cohort and 0·901 (95% CI: 0·831–0·971) in the validation cohort. The calibration curve exhibited good agreement between the values predicted by the nomogram and the actual measurements. The decision curve graphically suggested the predictive model yielded a higher net benefit than both the “treat-all” and “treat-none” strategies.
This nomogram is the first predictive model incorporating pathological factors for IgAVN progression which is adequately calibrated in both internal and external validation. It may facilitate early risk stratification and personalized interventions to improve patient outcomes.
